Cellectis SA is primarily active in the biotechnology industry.

The main competitors of Cellectis SA in the market include companies such as Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics.

Cellectis SA is a biopharmaceutical company specializing in the development of innovative immunotherapies for patients with cancer. Founded in 1999, Cellectis has since been at the forefront of gene editing and engineered cell-based therapies. The company heavily focuses on harnessing the potential of allogeneic CAR-T cells to revolutionize cancer treatment. Cellectis has a rich history of pioneering advancements in gene editing, with its proprietary technology, TALEN® being recognized worldwide. By leveraging its expertise in genome engineering, Cellectis aims to provide safer, more effective treatments for patients in need. With a strong commitment to research and development, Cellectis continues to make significant contributions to the field of immunotherapy.

Cellectis SA has achieved several significant milestones in its journey. Over the years, the company has made remarkable progress in the field of gene editing and cell therapy. One of its notable accomplishments is the successful development of its proprietary gene-editing technology known as TALEN®. This groundbreaking technology enables precise and efficient modification of genetic material, offering immense potential in various applications, including the treatment of genetic diseases and the creation of gene-edited cell therapies. Additionally, Cellectis SA has also achieved noteworthy partnerships and collaborations within the pharmaceutical and biotech industries, further solidifying its position as a leader in the field. These milestones exemplify the company's commitment to advancing cutting-edge genetic engineering solutions.

Cellectis SA is primarily present in various countries and regions across the globe. The company has a strong presence in the United States, where it has established multiple research and development facilities. Cellectis SA also has significant operations in Europe, including France and Germany, where it conducts various specialized activities related to gene editing and cell therapy. Additionally, the company has expanded its reach into Asia, particularly in Japan, through collaborations and strategic partnerships. With its global footprint, Cellectis SA is well-positioned to leverage its innovative technologies and solutions in the field of gene editing and cell therapy across different markets.

Cellectis SA represents the values of innovation, collaboration, and integrity. The company's corporate philosophy revolves around advancing the field of precision medicine through the development of gene-edited cell therapies. Cellectis SA is committed to driving scientific advancements to enhance patient outcomes and improve quality of life. By leveraging its expertise in gene editing and genome engineering, the company aims to harness the power of the human immune system to treat various diseases, including cancer. Through continuous research and development, Cellectis SA is dedicated to transforming the future of healthcare and making a positive impact on patients' lives.

Analysts currently set an average price target of 7,65 USD for the Cellectis stock (median: 7,65 USD), implying +148,0 % versus the latest price. The consensus is based on 13 analyst ratings.

Cellectis Analyytikkojen kursstavoitteet 2026

13 analysts currently rate the Cellectis stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Cellectis to generate revenue of 57,68 M USD and earnings per share of −0,88 USD.

Cellectis Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Cellectis share trades at 2,68 EUR (3,08 USD).

The Cellectis share (ALCLS.PA) is listed on 7 stock exchanges, including: Frankfurt (ZVA.F), München (ZVA.MU), Düsseldorf (ZVA.DU), London (0WA2.L), Paris (ALCLS.PA).

Cellectis SA is a leading biotechnology company focused on developing innovative CAR-T cell therapies for patients with cancer and other serious diseases. The company is headquartered in Paris, France, and has offices in the US and Singapore. Cellectis SA's business model is based on three different divisions: clinical development of CAR-T cell therapies, delivery of solutions for genetic cell editing, and development of agricultural products through genome editing. In the field of clinical development of CAR-T cell therapies, Cellectis SA has developed a wide range of products targeting different types of cancer. The company's products include UCART19, UCART22, UCART123, and UCARTCS1, all of which are based on genetically modified T cells programmed to recognize and destroy cancer cells. Additionally, Cellectis SA is involved in the delivery of solutions for genetic cell editing. The company offers a wide range of technologies including Transcription Activator-Like Effector Nucleases (TALEN) and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology. These technologies allow researchers to make targeted changes to cell genomes for the treatment of diseases or improvement of agricultural yields. Furthermore, Cellectis SA has a division focused on the development of agricultural products through genome editing. The company utilizes its technologies to enhance plants and livestock and achieve higher yields. It has also formed a partnership with Monsanto. Overall, Cellectis SA is dedicated to developing innovative solutions in various areas including clinical development of CAR-T cell therapies, genetic cell editing, and improvement of agricultural products. The company has a broad portfolio of products and technologies that enable it to operate in diverse fields. Additionally, it has a strong research and development department that continuously improves its products and technologies and develops new solutions. Thanks to its innovative solutions, Cellectis SA has established a strong position in the biotechnology industry in recent years. The company has a wide range of customers and partners around the world, and its products and technologies are utilized by many researchers and scientists globally. In conclusion, Cellectis SA's business model is focused on developing innovative solutions in various areas, and the company has a wide range of products and technologies that enable it to operate in diverse fields.

odotettu liikevaihto Cellectis on 57,68 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Cellectis on −79,43 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Cellectis:n hinta-voitto-suhde (P/E) on tällä hetkellä −3,52. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Cellectis-osakkeen arvostusta.

Cellectis:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,84. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Cellectis-osakkeen arvostuskennuslukuna.

Cellectis:n Eulpool-laatuscore on 4/10.

Cellectis:n ISIN on FR0010425595. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Cellectis:n WKN on A0MKPR. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Cellectis:n ticker on ALCLS.PA. Tämä pörssinoteeraus käytetään Cellectis-osakkeiden kauppaan pörssissä.

Cellectis maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Cellectis kuuluu sektoriin 'Terveydenhuolto'.

Cellectis:n osingot jaetaan valuutassa USD.